Fondazione Policlinico Universitario Agostino Gemelli IRCCS Largo A. Gemelli, 8 Roma
Dipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica
BRCA Awareness in 2020
September 29th, 2020
Rome
DIRETTORE DELLA SCUOLA CLASS:
Prof. Giovanni Scambia, Università Cattolica del Sacro Cuore – Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma
DIRETTORE DEL CORSO:
Prof.ssa Anna Fagotti, Università Cattolica del Sacro Cuore – Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma
RESPONSABILI SCIENTIFICI:
Dott.ssa Claudia Marchetti, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS;
Dott.ssa Antonella Pietragalla, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma
FACULTY
Fagotti Anna
Università Cattolica del Sacro Cuore – Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma
Fruscio Robert
Università degli Studi di Milano-Bicocca; ASST Monza – San Gerardo Hospital
Genuardi Maurizio
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma
Manchanda Ranjit
Wolfson Institute of Preventive Medicine, Barts Cancer Research UK Centre, Queen Mary University of London
Marchetti Claudia
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma
Minucci Angelo
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma
Paris Ida
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma
Pietragalla Antonella
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma
Salutari Vanda
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma
Steenbeek Miranda
Radboud university medical centre Nijmegen, the Netherlands
Scambia Giovanni
Università Cattolica del Sacro Cuore – Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma
Testa Antonia Carla
Università Cattolica del Sacro Cuore – Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma
AIM
Deleterious mutations in DNA repair pathways, including breast-cancer susceptibility gene 1 (BRCA1) and breast-cancer susceptibility gene 2 (BRCA2) mutation carries, predispose to an elevated risk for several familial tumor types, such as ovarian cancer (OC), breast cancer and prostate cancer.
In this scenario, due to its poor prognosis, OC management remains a major clinical problem and an in-depth analysis of the genomic landscape has gained a growing importance in the last few years. Women who carry a BRCA 1/2 mutation have long been known to present a substantial increased lifetime risk of OC development. Currently, several OC screening programs, including a detailed family history, clinical examination, transvaginal ultrasound and/or serum CA-125 on an annual basis, have been proposed and might be able to reduce OC incidence and mortality in this setting of patients [5]. The aim is to identify women population that could benefit from screening program as a means of early detention and possible prevention of advanced-stage disease. Available literature data do not support a definitive ovarian screening recommendation and the the lack of consistent screening methods of early OC detection, as well as the poor OC prognosis mentioned above, have worldwide elected the risk-reducing surgery as the most effective prophylactic measure for reducing OC risk in BRCA carries [6], [7]. This approach has raised many questions, especially on several aspects of health and patient’s quality of life (QoL).
This conference provides highlights in current risk-reducing OC strategies to potentially suggest a more tailored treatment approach in patients with BRCA1 and/or BRCA2 mutations.
SCIENTIFIC PROGRAM
10.00 Introduction and Coffee
10.20 Current guidelines of Brca testing, Maurizio Genuardi
10.40 Pros and Cons of Universal Screening of Women for BRCA Mutations, Ranjit Manchanda
11.00 Risk Reducing options, Claudia Marchetti
11.20 Opportunistic salpingectomy and delayed oophorectomy. Evidences and prospectives, Miranda Steenbeek
11.40 Results from SOLO-trials and PAOLA-1, Vanda Salutari
12.00 Brca-related cancers other than Ovary. How should we prevent? Ida Paris
12.20 Genetic Counselling: physician & patient’s prospective, Antonella Pietragalla
12.40 Discussion, All
13.00 Lunch
14.00 Somatic or germline BRCA/HRD assessment: differences and interpretation, Angelo Minucci
14.20 BRCA Registry Project (sponsored by SIGO): which efforts, which expectations? Robert Fruscio
14.40 BRCA radiologic assessment: something different? Antonia Carla Testa
15.00 BRCA UNIT: our proposal, Giovanni Scambia
15.20 Discussion and Closing Remarks, All
SEDE DEL CORSO
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Largo A. Gemelli,8 – 00168, Roma
Dipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica
Aule 505-506-507-508, V piano, ala A
CREDITI FORMATIVI
Sono stati attribuiti n. 4 crediti ECM per le seguenti categorie:
- MEDICO CHIRURGO
- Discipline: GENETICA MEDICA; GINECOLOGIA ED OSTETRICIA; ONCOLOGIA
REGISTRATIONE
La registrazione può essere effettuata collegandosi al sito www.obegyn.com
L’iscrizione al corso è gratuita
La conferma di avvenuta ammissione al corso dovrà pervenire, via e-mail, dalla segreteria Molipharma (info@molipharma.com), successivamente alla compilazione della scheda di registrazione.
I
PROVIDER
Via Ravenna, 9C 00161 – Roma (Italy)
Tel +39 06 83393669 Fax +39 06 89283835
Web: www.medical-net.it
accreditato dalla Commissione Nazionale ECM n° 256
Con il contributo non condizionante di:
